Vaccine Technologies Market Report 2026

The vaccine technologies market size has grown rapidly in recent years. It will grow from $61.38 billion in 2025 to $67.71 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to expansion of national immunization initiatives, increased public health funding, advancements in vaccine production technologies, growth in infectious disease surveillance, establishment of global vaccine supply chains.

The vaccine technologies market size is expected to see strong growth in the next few years. It will grow to $99.04 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing investments in next-generation vaccine platforms, rising demand for pandemic preparedness solutions, expansion of adult vaccination programs, growing focus on non-infectious disease vaccines, increasing adoption of digital vaccine tracking systems. Major trends in the forecast period include increasing development of mrna and recombinant vaccines, rising focus on rapid vaccine manufacturing platforms, growing adoption of novel delivery technologies, expansion of global immunization programs, enhanced emphasis on cold chain optimization.

The rising prevalence of infectious diseases is expected to drive the growth of the vaccine technologies market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which can spread directly or indirectly between individuals. The increase in infectious disease prevalence is largely due to heightened travel, which accelerates the cross-border transmission of pathogens. Vaccine technologies support the management of infectious diseases by triggering targeted immune responses, helping to prevent infections and control outbreaks. They enhance public health efforts by reducing disease transmission and severity, thereby improving overall healthcare outcomes. For example, in February 2024, according to the UK Health Security Agency, a UK-based government organization, tuberculosis cases in England rose to 4,850 in 2023, marking a 10.7% increase from 4,380 cases in 2022. Therefore, the rising prevalence of infectious diseases is fueling the growth of the vaccine technologies market.

Key companies in the vaccine technologies market are focusing on developing innovative solutions, such as quadrivalent influenza vaccines, to provide broader immunization coverage and reduce the risk of strain mismatch. Quadrivalent influenza vaccines are designed to protect against four influenza virus strains - two influenza A and two influenza B strains - offering wider protection than trivalent vaccines. For instance, in February 2025, Zydus Lifesciences, an India-based pharmaceutical company, launched VaxiFlu-4, a quadrivalent influenza vaccine. The vaccine provides seasonal protection against four influenza strains, including both A and B types, and is administered as a single-dose intramuscular injection suitable for both adults and children. It helps lower the burden of seasonal influenza by delivering broader strain coverage compared to conventional trivalent vaccines.

In December 2023, AstraZeneca plc, a UK-based biopharmaceutical company, acquired Icosavax Inc. for $1.1 billion. Through this acquisition, AstraZeneca aims to strengthen its respiratory vaccine portfolio by incorporating Icosavax’s protein virus-like particle (VLP) platform, which includes the phase III-ready combination vaccine candidate IVX-A12 targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Icosavax is a US-based biotechnology company specializing in vaccine technologies, particularly in the development of virus-like particle (VLP)-based vaccines for respiratory illnesses.

Major companies operating in the vaccine technologies market are Pfizer Inc, Johnson And Johnson, Merck And Co Inc, Sanofi SA, AstraZeneca Plc, GSK Plc, Moderna Inc, CSL Limited, Bharat Biotech International Limited, Bavarian Nordic AS, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd, Emergent BioSolutions Inc, Valneva SE, Novavax Inc, Dynavax Technologies Corporation, CureVac NV, Inovio Pharmaceuticals Inc, Serum Institute Of India Pvt Ltd, BioNTech SE, Panacea Biotec Ltd, Biological E Limited.

North America was the largest region in the vaccine technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vaccine technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vaccine technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the vaccine technologies market by increasing costs of imported bioreactors, filtration systems, cold storage equipment, raw materials, and specialized manufacturing components. Vaccine manufacturers in North America and Europe are most affected due to reliance on imported production infrastructure, while Asia-Pacific faces higher costs for export-oriented vaccine manufacturing. These tariffs are increasing production expenses and affecting pricing strategies. However, they are also promoting domestic vaccine manufacturing, regional supply chain strengthening, and long-term investments in self-sufficient vaccine production capabilities.

The vaccine technologies market research report is one of a series of new reports that provides vaccine technologies market statistics, including vaccine technologies industry global market size, regional shares, competitors with a vaccine technologies market share, detailed vaccine technologies market segments, market trends and opportunities, and any further data you may need to thrive in the vaccine technologies industry. This vaccine technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vaccine technologies refer to the scientific methods and tools used to develop, produce, and deliver vaccines that stimulate the immune system to recognize and fight pathogens such as viruses, bacteria, or other harmful microorganisms. The main purpose of these technologies is to safely induce immunity, prevent illness, and control the spread of infectious diseases.

The primary types of vaccine technologies are recombinant/conjugate/subunit vaccines, inactivated vaccines, live attenuated vaccines, and toxoid vaccines. Recombinant, conjugate, or subunit vaccines use specific components of a pathogen, such as proteins or sugars, instead of the whole microorganism, to safely stimulate an immune response. These vaccines are administered through various routes, including parenteral, oral, and nasal delivery, and are applied for both infectious and non-infectious disease indications. Vaccine technologies cater to all age groups, including pediatric and adult populations, and are distributed through multiple channels, such as hospitals, retail pharmacies, government suppliers, and other healthcare outlets.

The vaccine technologies market consists of revenues earned by entities by providing services such as vaccine research and development, formulation and testing, clinical trials management, regulatory support, manufacturing process optimization, and distribution logistics for vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. The vaccine technologies market also includes sales of mRNA vaccines, viral vector vaccines, protein subunit vaccines, and related raw materials and reagents used in vaccine development and production. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.